X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
female (18) 18
oncology (18) 18
male (17) 17
aged (15) 15
lung neoplasms - drug therapy (13) 13
adult (12) 12
middle aged (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
drug administration schedule (7) 7
index medicus (7) 7
neoplasm staging (7) 7
survival rate (7) 7
treatment outcome (7) 7
chemotherapy (6) 6
lung neoplasms - mortality (6) 6
lung neoplasms - pathology (6) 6
paclitaxel (6) 6
antineoplastic agents - pharmacokinetics (5) 5
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
carboplatin (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
carcinoma, small cell - drug therapy (5) 5
cisplatin (5) 5
maximum tolerated dose (5) 5
pharmacology & pharmacy (5) 5
survival (5) 5
aged, 80 and over (4) 4
antineoplastic agents - administration & dosage (4) 4
cancer (4) 4
carboplatin - administration & dosage (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
care and treatment (4) 4
clinical trials (4) 4
follow-up studies (4) 4
lung cancer, non-small cell (4) 4
paclitaxel - administration & dosage (4) 4
prognosis (4) 4
respiratory system (4) 4
bortezomib (3) 3
clinical-trials (3) 3
combination (3) 3
cooperative-oncology-group (3) 3
dexamethasone - administration & dosage (3) 3
disease progression (3) 3
dose-response relationship, drug (3) 3
etoposide (3) 3
gemcitabine (3) 3
medicine & public health (3) 3
neoplasm recurrence, local - drug therapy (3) 3
paclitaxel - adverse effects (3) 3
pharmacokinetics (3) 3
quality of life (3) 3
survival analysis (3) 3
administration, oral (2) 2
analysis (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
area under curve (2) 2
article (2) 2
bortezomib - administration & dosage (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
carboplatin - adverse effects (2) 2
carboplatin - pharmacokinetics (2) 2
carcinoma, non-small-cell lung - surgery (2) 2
carcinoma, small cell - mortality (2) 2
carcinoma, small cell - radiotherapy (2) 2
cell lung-cancer (2) 2
cells, cultured (2) 2
chemotherapy, adjuvant (2) 2
cisplatin - administration & dosage (2) 2
combined modality therapy (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease-free survival (2) 2
diseases (2) 2
docetaxel (2) 2
etoposide - administration & dosage (2) 2
forthcoming 7th edition (2) 2
infusions, intravenous (2) 2
leukemia (2) 2
lung cancer (2) 2
lung neoplasms - radiotherapy (2) 2
lung neoplasms - surgery (2) 2
metaanalysis (2) 2
multiple myeloma - drug therapy (2) 2
nausea - chemically induced (2) 2
non-small cell lung cancer (2) 2
oligopeptides - administration & dosage (2) 2
oligopeptides - adverse effects (2) 2
pharmacology (2) 2
phase-i (2) 2
plasma (2) 2
product development (2) 2
proteasome inhibitor (2) 2
randomized trial (2) 2
randomized-trial (2) 2
retreatment (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 31, pp. 5043 - 5051
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2008, Volume 26, Issue 4, pp. 650 - 656
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 300 - 300
Abstract Introduction Treatment of CLL is rapidly evolving, now including oral targeted agents and novel combinations. However, complete response (CR) rates... 
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2016, Volume 34, Issue 2, pp. 216 - 224
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2012, Volume 7, Issue 11, pp. 1683 - 1690
Despite complete surgical resection survival in early-stage non–small-cell lung cancer (NSCLC) remains poor. On the basis of prior preclinical evaluations, we... 
Histone deacetylase | Proteasome inhibitor | Lung cancer | FORTHCOMING 7TH EDITION | APOPTOSIS | TRANSCRIPTIONAL ACTIVATION | TNM CLASSIFICATION | DESCRIPTORS | VORINOSTAT | STAGING PROJECT | PROPOSALS | GENE | ONCOLOGY | RESPIRATORY SYSTEM | EXPRESSION | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Pyrazines - administration & dosage | Carcinoma, Squamous Cell - surgery | Lung Neoplasms - pathology | Male | Gene Expression Profiling | Immunoenzyme Techniques | Aged, 80 and over | Biomarkers, Tumor - metabolism | Hydroxamic Acids - administration & dosage | Female | Boronic Acids - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Bortezomib | Carcinoma, Non-Small-Cell Lung - surgery | Histone Deacetylases - chemistry | Proteasome Endopeptidase Complex - chemistry | Combined Modality Therapy | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Large Cell - surgery | Lung Neoplasms - surgery | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Adenocarcinoma - surgery | Index Medicus | lung cancer | proteasome inhibitor
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 203 - 203
Abstract Abstract 203 Background: Oprozomib (OPZ, formerly ONX 0912), a structural analog of carfilzomib (CFZ), is an orally bioavailable, next-generation... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1844 - 1844
Abstract Introduction: Carfilzomib is a selective proteasome inhibitor that is approved in the United States and other countries for the treatment of relapsed... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 30 - 30
Abstract Introduction: Single-agent carfilzomib has previously shown activity in patients with relapsed and refractory multiple myeloma (MM) who have high-risk... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 729 - 729
Abstract Introduction: The randomized phase 3 ENDEAVOR study (NCT01568866; N=929) demonstrated that carfilzomib and dexamethasone (Kd) significantly improved... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4250 - 4250
Abstract Introduction: The ENDEAVOR study found that Kd was superior to Vd, with a 2-fold improvement in median PFS (18.7 vs 9.4 mo; HR=0.53; 95% CI,... 
Journal Article
Current Oncology Reports, ISSN 1523-3790, 8/2006, Volume 8, Issue 4, pp. 258 - 264
Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the... 
Medicine & Public Health | Oncology | Lung Neoplasms - drug therapy | Prognosis | Humans | Salvage Therapy | Quality of Life | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
Journal Article